Table 1.
Summary of outcomes and antimicrobial therapy for carbapenemase-producing K. pneumoniae infections found in tier 1 articles
| First Author (no. of subjects) [References] | Clinical failured | Microbiologic failured | Mortality | Combination antimicrobial therapy | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PMB/COL | TCN | AMG | CARB | FOS | PCN | FQ | ||||
| Ariza-Heredia (n = 1) [18] | – | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Balandin Moreno (n = 3) [31] | – | 2/3 (66.7%) | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) | 1/3 (33.3%) | 2/3 (66.7%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Camargo (n = 1) [19] | – | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Chuaa (n = 2) [20] | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Cicora (n = 5) [32] | – | 4/5 (80%) | 1/5 (20%) | 3/5 (60%) | 5/5 (100%) | 0/5 (0%) | 3/5 (60%) | 4/5 (80%) | 0/5 (0%) | 0/5 (0%) |
| Clancy (n = 1) [33] | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| de Sanctis (n = 1) [21] | – | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Giamarellou (n = 1) [22] | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) |
| Lemmenmeier (n = 3) [23] | 0/3 (0%) | – | 0/3 (0%) | 3/3 (100%) | 3/3 (100%) | 0/3 (0%) | 3/3 (100%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Lubbert (n = 4) [37] | 3/4 (75.0%) | – | 3/4 (75%) | 4/4 (100%) | 4/4 (100%) | 4/4 (100%) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Maltezou (n = 2) [38] | 0/2 (0%) | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Marquezb (n = 1) [24] | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Mathersc (n = 1) [25] | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) |
| Morris (n = 1) [39] | 0/1 (0%) | – | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Mouloudi (n = 4) [40] | 1/4 (25.0%) | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) | 4/4 (100%) | 4/4 (100%) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Navarro (n = 2) [41] | – | – | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Nevrekar (n = 1) [26] | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Olivaa (n = 1) [27] | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Pontikis (n = 9) [28] | 5/9 (55.6%) | 4/9 (44.4%) | 4/9 (44.4%) | 8/9 (88.9%) | 4/9 (44.4%) | 2/9 (22.2%) | 3/9 (33.3%) | 9/9 (100%) | 2/9 (22.2%) | 0/9 (0%) |
| Sanchez-Romero (n = 1) [47] | – | – | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Souli (n = 6) [43] | 3/6 (50%) | 3/6 (50%) | 5/6 (83.3%) | 6/6 (100%) | 3/6 (50%) | 3/6 (50%) | 4/6 (66.7%) | 0/6 (0%) | 2/6 (33.3%) | 2/6 (33.3%) |
| Viaggi (n = 1) [29] | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) |
| Virgilio (n = 1) [30] | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) |
| N = 53 | 14/39 (35.9%) | 22/42 (52.4%) | 19/53 (35.8%) | 47/53 (88.6%) | 39/53 (73.6%) | 26/53 (49.1%) | 23/53 (43.4%) | 16/53 (30.2%) | 5/53 (9.4%) | 4/53 (7.5%) |
PMB polymyxin B, COL colistin, TCN tetracycline, AMG aminoglycoside, CARB carbapenem, FOS fosfomycin, PCN penicillin, FQ fluoroquinolone
aDual carbapenem therapy used
bRifampin also administered
cTrimethoprim–sulfamethoxazole also administered
dDash indicates information was unavailable